Form 4: Codexis CEO Stephen Dilly Reports Stock and Option Transactions
SEC Form 4 Filing
Stephen Dilly, CEO of Codexis, reports acquisition of restricted stock units and stock options, along with holdings in common stock.
Summary
- On February 5, 2025, Stephen Dilly, the President and CEO of Codexis, reported transactions involving Codexis common stock and stock options.
- Dilly acquired 88,750 restricted stock units, which vest in three equal annual installments from the grant date.
- He also acquired 532,500 stock options with an exercise price of $4.37, vesting over four years with a monthly component after the first year.
- Following these transactions, Dilly beneficially owns 673,053 shares of common stock and 532,500 stock options.
- The reported transactions include 2,000 shares acquired under the Employee Stock Purchase Plan on May 10, 2024.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of shares and options suggests confidence, but it's not overwhelmingly positive.
Positives
- The acquisition of stock options and restricted stock units by the CEO could be interpreted as a sign of confidence in the company's future performance.
Future Outlook
The vesting schedules of the restricted stock units and stock options indicate a multi-year commitment from the CEO.
Industry Context
Form 4 filings are routine disclosures for corporate insiders and provide transparency into their trading activities. These filings are closely watched by investors for signals about management's view of the company's prospects.
Comparison to Industry Standards
- Stock option grants and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
- Vesting schedules are generally structured to incentivize long-term performance and retention, which is standard practice across comparable companies.
Stakeholder Impact
- The transactions could influence investor sentiment regarding the company's leadership and future prospects.
Key Dates
| Date | Description |
|---|---|
| May 10, 2024 | Acquisition of 2,000 shares under the Employee Stock Purchase Plan |
| February 5, 2025 | Grant date of restricted stock units and stock options |
| February 5, 2025 | Date of earliest transaction reported |
| February 7, 2025 | Date of signature on the Form 4 filing |
| February 5, 2035 | Expiration date of stock options |
Keywords
Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Codexis, CDXS, Stephen Dilly, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.